Printer Friendly

Single Intramuscular Methylprednisolone dose in Asthma and Chronic Obstructive Pulmonary Disease Patients on Discharge.

Byline: Jawed Abubaker, Fatima Zaina, Shanulhaq Siddiqui, Maria Zahid, Syed Zia Ullah, Zain Jawed Abubaker, Musa Karim and Saleem Ullah

Keywords: Intramuscular, Methylprednisolone, Asthma, COPD, Steroids.

Introduction

Chronic respiratory diseases contribute a significant share to the increasing global burden of non - communicable diseases. With common manifestations such as asthma, which is reversible, and chronic obstructive pulmonary disease (COPD) which is irreversible, mortality from the latter was found to be eight times more common than asthma.1,2 COPD ranked the third leading cause of global mortalities in 2010, and by 2030 it is projected to be the fourth leading cause of global deaths.3,4 According to World Health Organisation (WHO) fact sheet, COPD accounted for around 5% (3.17 million) of the total global fatalities5 in 2015. In 2012, the World Health Assembly embarked upon a 25 by 25 goal to reduce premature mortalities caused by non-communicable diseases including COPD by 25% by the year 2025.6

Despite all the efforts made by the global community, a systematic review of COPD's global prevalence reported growing trends worldwide, as well as at regional levels.7 Chronic obstructive pulmonary disease (COPD) is a non-curable but treat able and preventable disease, characterised by symptoms such as airflow limitation and persistent respiratory symptoms due to abnormalities in airway and/or alveolar.8 In developed counties COP Dis associated with smoking and occupational exposures, while the leading cause of COPD in low and middle income countries is the domestic use of bio mass fuel for cooking and heating. 9-1 1

Both progressive and chronic patients of COPD, often experience short episodes of aggravated respiratory symptoms. At least one episode of exacerbation per year is reported in 3.8% to 29.5% of these patients.12, 13 Patients with exacerbation of Chronic Obstructive Lung Disease or asthma receive systemic steroids during hospitalisation and also at the time of discharge. The benefit of steroid therapy is well established, 14, 15 however, the rate of relapse remains high, 10% to 12% in such patients.16-18 General guidelines exist for the dosage and duration of steroids.19, 20 In hospital, the dosages are generally at par with the recommendations, but the discharge dose depends upon the primary physician and it varies not only in the level of dosage but the duration of the dosage as well, which has led to a significant issue for the safety of patients.

At the same time, based on our experience, it has been observed that patients who were using steroids on their own unsupervised, either under or overuse medication which leads to their frequent re-admissions in hospitals with exacerbations, and occasionally presenting life threatening status. Past studies advocate the administration of intramuscular injections as safe, and as effective as oral steroid therapy, suggesting it as an effective alternative for patients with asthma or COPD who are at high risk for non-adherence or unwilling to take oral therapy.16,21-25 We postulate a single dose of methylprednisolone in our population is a safe strategy at the time of discharge after acute exacerbation of asthma and COPD. Therefore, in this pilot study we aimed to evaluate the safety of a single intramuscular methylprednisolone (IM) in our population at the time of discharge as a replacement of oral steroid therapy for the patients with asthma or COPD.

Methods

Approval for this pilot study was obtained from the institution ethical review board ERC # 06/2018. It was a proof-of-concept, open label clinical tr ial without randomisation, with the primary end to evaluate the safety of administering a single intra muscular methylprednisolone (IM) at the time of discharge in patients with asthma or COPD in our population. Study was co nd uc ted at the Pulmonar y Depar tme nt of Ziauddin Hospital and University, Karachi from January 2018 to March 2018. Patients between the ages of 18-75 who were ready to be discharged after in-hospital treatment for exacerbations of either asthma or COPD were recruited for this study. Prior to inclusion, the risks, benefits and safety protocol were explained to all the patients and their guardians or legal care takers and an inform consent was taken for participation in this study. Permission of their primary physician was also obtained.

Those patients with any contraindication to intramuscular injections, as per their primary physician, were excluded from this study. Pertinent information regarding patients' medical condition including diabetes control, body weight, blood pressure were collected as well as contact numbers of the patients, their guardians or legal care taker were also obtained. At the time of discharge, all enrolled patients were given an intramuscular injection of methylprednisolone. Injection site was documented and all the patients were followed-up through telephonic calls one week and one month after their discharge. Information on the rescue - use of short - acting bronchodilator inhalers as well as nebuliser and any visit to the emergency room or doctor's clinic other than booked appointment were obtained.

Patients' self-reported information about their blood sugar, blood pressure control, symptoms suggestive of oral thrush, acid reflux symptoms such as increased gastric acidity, and information on weight gain were also recorded. The collected information was analysed using SPSS version 21. Frequency and percentages were calculated for categorical variables and mean+-standard deviation (SD) was calculated for continuous variables.

Table-1: Baseline characteristics of the patients.

Baseline Characteristics###n(%)

Gender

###Male###17(56.7)

###Female###13(43.3)

Age [Mean ]###52.83+-14.27 years

###18 to 50 years###10(33.3)

###51 to 75 years###20(66.7)

Body Mass Index(BMI) [Mean ]###22.43+-4.52 kg/m2

###Weight [Mean]###62.93+-13.76 kg

###Height [Mean]###167.33+-7.89 cm

Medical Condition

###Asthma###19(63.3)

###COPD###11(36.7)

Table-2: Follow-up.

Outcome###n(%)

Unscheduled emergency room visits###0(0.0)

Symptoms of oral thrush###2(6.7)

Weight gain in one week###1(3.3%)

Weight gain in one month###5(16.7)

Glycaemic control###30(100.0)

Nocturnal symptoms###0(0.0)

Awakening###0(0.0)

Dyspepsia###0(0.0)

Results

Baseline characteristics

A total of 30 patients were recruited for this pilot study. Telephonic follow-up was conducted once a week and once a month for all 30 patients recruited for the study. The mean +- SD age was 52.83 +- 14.27 years, and 17 (56.7%) patients were male. The mean +- SD body mass index (BMI) was 22.43 +- 4.52 kg/m2. Majority of the patients, 19 (63.3%) had asthma. Baseline characteristics of the patients are presented in Table 1.

Follow-up

Outcome after one month of follow-up is presented in Table 2. One month after discharge, no unscheduled emergency room visits was observed in all the study patients. Symptoms suggestive of oral thrush was observed in only 2 (6.7%) patients and weight gain after one week and one month was reported by 1 (3.3%) and 5 (16.7%) of the patients respectively. Controlled blood sugar and blood pressure was repor ted by all the patients. Also during the follow-up period of one month no incidence of nocturnal symptoms, awakening and dyspepsia were reported. Rescue-use of short-acting bronchodilator inhalers as well as nebuliser is presented in Figure 1.

Discussion

Aim of this pilot study was to evaluate the safety of administering a single intramuscular methylprednisolone (IM) in patients with asthma or COPD at the time of discharge. Steroids are one of the most important drugs, especially for the management of asthma exacerbations and to a large extent for COPD as well. Almost all patients are discharged on oral tapering dose of steroids.4,8,16 In the absence of strong guideline recommendations,8 many physicians choose their own strategy which may vary from one patient to the other; also sometimes the different medical departments, mainly internal medicine and pulmonary administer their own discharge protocols. In our study, patients who received a single shot of intramuscular methylprednisolone (IM) at the time of hospital discharge, reported no visits to the emergency room or doctor's clinic, no incidence of nocturnal awakenings and dyspepsia during the follow-up period of one month.

Only 2 (6.7%) patients reported symptoms suggestive of oral thrush, and 5 (16.7%) reported weight gain, while all the patients reported controlled sugar and blood level. Findings from our study suggest that at the time of discharge, the admi nistration of a single intramuscular methylprednisolone (IM) in patients with either asthma or COPD is safe. Our findings are the same as the studies conducted in other populations.16,21-25 Patients usually get discharged from hospitals prescribed with several different forms of drugs such as inhalers or nebulisation or oral medication for other comorbid conditions. Oral medication with confusing instructions on tapering is not only difficult for the well informed patients, but it is most difficult for patients who are either not educated or are guided by a family member. This may either lead to non-adherence of medication or under or overuse of drugs, which can result in repeated hospital visits for these patients.

Limitations and Recommendations for future researches:

This pilot study was conducted on a small sample of patients and clinical efficacy of intra muscular methylprednisolone was not studied in our population. Further research among patients with asthma and COPD is needed to assess the clinical efficacy of a single intramuscular methylprednisolone (IM) injection as a replacement for oral steroid therapy.

Conclusion

A single dose of methylprednisol one injection administered to patients with asthma and COPD without any sideeffects observed for over one month demonstrated a safe strategy. In an effort to avoid confusion and under and overuse of steroids, the use of a single dose of intramuscular methylprednisolone could be considered in clinical practice.

Disclaimer: None to declare.

Conflict of Interest: None to declare.

Funding Sources: None to declare.

References

1. Soriano JB, Abajobir AA, Abate KH, Abera SF, Agrawal A, Ahmed MB, et al. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med 2017; 5: 691-706.

2. Beran D, Zar HJ, Perrin C, Menezes AM, Burney P. Burden of asthma and chronic obstructive pulmonary disease and access to essential medicines in low-income and middle-income countries. Lancet Respir Med 2015; 3: 159-70.

3. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095-128.

4. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonar y disease: GOLD executive summar y. Am J R espir Crit Care Med 2013; 187: 347-65.

5. WHO. Chronic obstructive pulmonary disease (COPD). [Online] 2017 [cited 2018 April 18]. Available from: URL: http://www.who.int/mediacentre/factsheets/fs315/en/.

6. Horton R. Non-communicable diseases: 2015 to 2025. Lancet 2013; 381: 509-10.

7. Adeloye D, Chua S, Lee C, Basquill C, Papana A, Theodoratou E, et al. Global and regional estimates of COPD prevalence: Systematic review and meta-analysis. J Glob Health 2015; 5: 020415

8. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global strategy for the diagnosis, management and prevention of chronic obstructive lung disease 2017 report. Respirology 2017; 22: 575-601.

9. Kurmi OP, Lam KB, Ayres JG. Indoor air pollution and the lung in low-and medium-income countries. Eur Respir J 2012; 40: 239-54.

10. Perez-Padilla R, Schilmann A, Riojas-Rodriguez H. Respiratory health effects of indoor air pollution. Int J Tuberc Lung Dis 2010; 14: 1079-86.

11. Salvi S, Barnes PJ. Is exposure to biomass smoke the biggest risk factor for COPD globally? Chest 2010; 138: 3-6.

12. van Gemert F, Kirenga B, Chavannes N, Kamya M, Luzige S, Musinguzi P, et al. Prevalence of chronic obstructive pulmonary disease and associated risk factors in Uganda (FRESH AIR Uganda): a prospective cross-sectional observational study. Lancet Glob Health 2015; 3: e44-51.

13. Choi SM, Lee J, Park YS, Lee CH, Lee SM, Yim JJ, et al. Prevalence and global initiative for chronic obstructive lung disease group distribution of chronic obstructive pulmonary disease detected by preoperative pulmonary function test. PloS One 2015; 10: e0115787.

14. Rowe BH, Spooner C, Ducharme F, Bretzlaff J, Bota G. Corticosteroids for preventing relapse following acute exacerbations of asthma. Cochrane Data base Syst Rev 2007; (3): CD000195.

15. Rowe BH, Spooner CH, Ducharme FM, Bretzlaff JA, Bota GW. Corticosteroids for preventing relapse following acute exacerbations of asthma. Cochrane Database Syst Rev 2007; (3): CD000195 (same as reference no. 14)

16. Krishnan JA, Davis SQ, Naureckas ET, Gibson P, Rowe BH. An umbrella review: corticosteroid therapy for adults with acute asthma. Am J Med 2009; 122: 977-91.

17. Papiris S, Kotanidou A, Malagari K, Roussos C. Clinical review: severe asthma. Crit Care 2001; 6: 30-44.

18. Edmonds ML, Camargo CA, Pollack CV, Rowe BH. The effectiveness of inhaled corticosteroids in the emergency department treatment of acute asthma: a meta-analysis. Ann Emerg Med 2002; 40: 145-54.

19. Wedzicha JA, Miravitlles M, Hurst JR, Calverley PM, Albert RK, Anzueto A, et al. Management of COPD exacerbations: A European respiratory society/American thoracic society guideline. Eur Respir J 2017; 49. pii: 1600791.

20. N ICE. Asthma: diagnosis, monitoring and chronic asthma management (NG80) [Online] 2017 [Cited 2018 April 18]. Available from: URL: https://www.nice.org.uk/guidance/ng80

21. Spaggiari L, Bertorelli G, Ridolo E, Morelli I, Guida L, Pigna F, et al. Exacerbations of severe asthma: a focus on steroid therapy. Acta Biomed 2014; 85: 205-15.

22. Moosavi ER. A comparative efficacy of oral prednisone with intramuscular triamcinolone in acute exacerbation of asthma. Iran J Allergy Asthma Immunol 2006; 5: 17-22.

23. Chan JS, Cowie RL, Lazarenk a GC, Little C, Scott S, Ford GT. Comparison of Intramuscular Betamethasone and Oral Pprednisone in the Prevention of Relapse of Acute Asthma. Can Respir J 2001; 8: 147-52.

24. Lahn M, Bijur P, Gallagher EJ. Randomized clinical trial of intramuscular vs oral methylprednisolone in the treatment of asthma exacerbations following discharge from an emergency department. Chest 2004; 126: 362-8.

25. Schuckman H, DeJulius DP, Blanda M, Gerson LW, DeJulius AJ, Rajaratnam M. Comparison of intramuscular triamcinolone and oral prednisone in the outpatient treatment of acute asthma: a randomized controlled trial. Ann Emerg Med 1998; 31: 333-8.
COPYRIGHT 2019 Knowledge Bylanes
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Journal of Pakistan Medical Association
Article Type:Report
Date:Jul 31, 2019
Words:2596
Previous Article:Health Screening as a tool to tackle the growing burden of Non-Communicable Diseases in Pakistan.
Next Article:Advances in structural heart disease: MitraClip for Secondary Mitral Regurgitation - A potential game changer.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters